PXN and prostate cancer: Abnormal paxillin expression is associated with many clinicopathological parameters such as aggressiveness, distant metastasis, and clinical stage in various tumors, including colorectal cancer [34], prostate cancer [35], salivary adenoid cystic carcinoma [36], and cervical cancer [31].